693285-60-8

Basic information

• Product Name: Boronic acid, (3-methoxy-2,6-dimethylphenyl)- (9CI)
• Synonyms: Boronic acid, (3-methoxy-2,6-dimethylphenyl)- (9CI)
• CAS NO: 693285-60-8
• Molecular Formula: C₉H₁₃BO₃
• Molecular Weight: 180.00872
• Product Categories: METHOXY
• Mol File: 693285-60-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Boronic acid, (3-methoxy-2,6-dimethylphenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Boronic acid, (3-methoxy-2,6-dimethylphenyl)- (9CI)(693285-60-8)
• EPA Substance Registry System: Boronic acid, (3-methoxy-2,6-dimethylphenyl)- (9CI)(693285-60-8)

Safety Data

• Hazardous Substances Data: 693285-60-8(Hazardous Substances Data)

Upstream product

• 74571-81-6 3-bromo-2,4-dimethylphenol 
• 576-22-7 2-Bromo-m-xylene 
• 693285-61-9 C₉H₉BrO₂ 
• 693285-59-5 3-bromo-2,4-dimethylbenzaldehyde 
• 23453-90-9 2-bromo-4-methoxy-1,3-dimethylbenzene 

Relevant articles and documents

3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES

The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

1-ARYL-4-SUBSTITUTED ISOQUINOLINES

1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.